OpenURL Connection Search

Select item for more details and to access through your institution.

The enhanced expression of estrogen‐related receptor α in human bladder cancer tissues and the effects of estrogen‐related receptor α knockdown on bladder cancer cells.
Published in:
Journal of Cellular Biochemistry, 2019, v. 120, n. 8, p. 13841, doi. 10.1002/jcb.28657
By:
- Ye, Xinqing;
- Guo, Jinan;
- Zhang, Hongxiang;
- Meng, Qinggui;
- Ma, Yun;
- Lin, Rui;
- Yi, Xianlin;
- Lu, Haoyuan;
- Bai, Xianzhong;
- Cheng, Jiwen
Publication type:
Article
Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
Published in:
Oncologist, 2019, v. 24, n. 8, p. e702, doi. 10.1634/theoncologist.2018-0839
By:
- Zhou, Ai‐Ping;
- Bai, Yuxian;
- Song, Yan;
- Luo, Hong;
- Ren, Xiu‐Bao;
- Wang, Xiuwen;
- Shi, Benkang;
- Fu, Cheng;
- Cheng, Ying;
- Liu, Jiyan;
- Qin, Shukui;
- Li, Jun;
- Li, Hanzhong;
- Bai, Xianzhong;
- Ye, Dingwei;
- Wang, Jinwan;
- Ma, Jianhui
Publication type:
Article
Cystitis glandularis: A controversial premalignant lesion.
Published in:
Oncology Letters, 2014, v. 8, n. 4, p. 1662, doi. 10.3892/ol.2014.2360
By:
- XIANLIN YI;
- HAOYUAN LU;
- YUEXIAN WU;
- YANG SHEN;
- QINGGUI MENG;
- JIWENG CHENG;
- YONG TANG;
- FENGXUE WU;
- RUBIAO OU;
- SHAOJUN JIANG;
- XIANZHONG BAI;
- KEJI XIE
Publication type:
Article
Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
Published in:
Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00664
By:
- Ma, Jianhui;
- Song, Yan;
- Shou, Jianzhong;
- Bai, Yuxian;
- Li, Hanzhong;
- Xie, Xiaodong;
- Luo, Hong;
- Ren, Xiubao;
- Liu, Jiyan;
- Ye, Dingwei;
- Bai, Xianzhong;
- Fu, Cheng;
- Qin, Shukui;
- Wang, Jinwan;
- Zhou, Ai-Ping
Publication type:
Article

Found: 4

The enhanced expression of estrogen‐related receptor α in human bladder cancer tissues and the effects of estrogen‐related receptor α knockdown on bladder cancer cells.

Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.

Cystitis glandularis: A controversial premalignant lesion.

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.